Physiologically‐based pharmacokinetic modelling of long‐acting injectable cabotegravir and rilpivirine in pregnancy

Documenti analoghi

• Physiologically based pharmacokinetic modeling of drug–drug interactions between ritonavir‐boosted atazanavir and rifampicin in pregnancy
  di: Shakir Atoyebi, et al.
  Pubblicazione: (2024)
• Clinical pharmacology considerations and drug–drug interactions with long‐acting cabotegravir and rilpivirine relevant to sub‐Saharan Africa
  di: Adrian Steulet, et al.
  Pubblicazione: (2024)
• Inter‐ and intraindividual variability of long‐acting cabotegravir/rilpivirine pharmacokinetics after 1 year of continuous use
  di: S. Sunagawa, et al.
  Pubblicazione: (2025)
• Pharmacokinetics of long‐acting cabotegravir and rilpivirine in seminal plasma throughout the dosing interval
  di: N. Neverette, et al.
  Pubblicazione: (2025)
• Minimal impact of pregnancy on rilpivirine pharmacokinetics: A POPPK approach
  Pubblicazione: (2024)